Medidata Rave Electronic Data Capture and Management Solution Selected by Leading Pharmaceutical Company

Medidata Solutions today announced that AstraZeneca (NYSE: AZN) has chosen to standardize on Medidata Rave® electronic clinical data capture (EDC), management and reporting solution as part of a plan to fully migrate to paperless clinical trials. Medidata Rave will help AstraZeneca replace its in-house EDC system and other EDC products for studies across all therapeutic categories in its diverse portfolio. AstraZeneca plans to implement Medidata Rave in many of its studies worldwide. As an early adopter of EDC technology, AstraZeneca previously relied on an in-house solution and has gained experience with other vendor solutions over the past five years. In 2005, AstraZeneca conducted an intensive review of a number of EDC products, which involved an evaluation of key requirements including functionality fit, the best fit with AstraZeneca’s strategic process, total cost of ownership, ease-of-use, and product look and feel. Medidata Rave met the highest percentage of AstraZeneca’s requirements and was selected for its strong architectural base, new technology, and user-friendly platform. "When it came down to it, the decision was clear. We needed a tool that would grow alongside us, rather than force us to make changes that would ultimately impact our user base,” said Robert Mullen, Global Project Leader for Medidata Rave Implementation at AstraZeneca. "AstraZeneca has high expectations for Medidata and Rave,” said Anders Ekblom, Vice President and head of Clinical Development at AstraZeneca. "When implemented, we look forward to achieving significant improvement in clinical efficiency, with the goal of improving overall time to market.” "We are delighted to strengthen our relationship with AstraZeneca, one of several of the world’s leading pharmaceutical companies that have recently decided to standardize on Medidata Rave,” said Tarek Sherif, CEO of Medidata Solutions. "AstraZeneca’s selection of Medidata Rave speaks to our ability to scale to accommodate any size company or trial and implement our solution as any sponsor’s standard for a web-based data capture system. We look forward to supporting AstraZeneca’s efforts to go paperless and achieve truly global electronic clinical trials.” About Medidata Solutions Worldwide Medidata Solutions helps the world’s leading pharmaceutical, biotechnology, medical device, and research organizations maximize the value of their clinical research investments. Innovative process design, technology and services streamline clinical trials by providing early visibility to reliable clinical data – the lifeblood of every research organization. Working with companies and institutions both large and small, Medidata Solutions helps clinical researchers safely accelerate the process of bringing life-enhancing treatments to market – on five continents and in more than 70 countries. Medidata Solutions brings significant value to its broad client base with deep clinical experience and expertise in more than 20 therapeutic areas, projects in Phase I, II, III, IV, registries and surveillance, and studies with thousands of investigators and tens-of-thousands of subjects. For more information, please visit www.mdsol.com. About AstraZeneca AstraZeneca (NYSE: AZN) is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $23.95 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. In the United States, AstraZeneca is a $10.77 billion healthcare business with more than 12,000 employees. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information about AstraZeneca, please visit: www.astrazeneca.com.